YOLFTbeta
Gelteq Limited Ordinary Shares

Gelteq Limited Ordinary Shares

GELS · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic

0.3803USD-0.00 (-0.13%)

Price History

Full chart

Market Stats

Previous Close0.3808
Open0.3801
Day Range0.38 – 0.4112
52-Week Range0.387 – 2.01
Volume13.29K
Market Cap5.85M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.52
Dividend Yield0.00%
50-Day Avg0.6113
200-Day Avg0.7147

About

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Nathan Jacob Givoni
  • Employees7
  • HeadquartersMonash Innovation Labs, Clayton, VIC, Australia, 3800, USA
  • Websitehttps://www.gelteq.com

Leadership

  • Mr. Nathan Jacob GivoniCo-Founder, CEO & Executive Director · b. 1984
  • Mr. Simon Hayden SzewachCo-Founder & Non-Executive Chairman · b. 1980
  • Ms. Thuy-Linh GiglerChief Financial Officer · b. 1980
  • Dr. Paul M. Wynne Ph.D.Chief Scientific Officer · b. 1963
  • Bradley Glenn KarpHead of Sales & Marketing
  • Mr. Adam BendellPresident of U.S. Operations
  • Mr. Matthew JonesHead of Sports Performance

Financials

Income Statement

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue-0147.54K79.84K0165.65K
Growth (%)----45.88%-100.00%-
Cost of Revenue-094.87K48.92K0-
Gross Profit-052.66K30.92K0165.65K
Gross Margin--35.69%38.72%-100.00%
Operating Expense-647.62K3.25M3.13M2.95M5.66M
Operating Income--647.62K-3.19M-3.10M-2.95M-5.50M
Operating Margin---2164.39%-3885.31%--3317.65%
EBITDA-527.23K-589.68K-1.98M-1.88M-1.75M-3.53M
EBITDA Margin---1341.45%-2349.87%--2129.76%
Net Income-375.59K-648.92K-3.37M-3.51M-3.55M-6.65M
Net Income Margin---2283.44%-4391.39%--4011.86%
R&D342.36K277.06K529.02K665.03K276.06K628.61K
R&D as % of Total Revenue--358.57%832.93%-379.49%
Interest Expense-1.30K174.50K403.52K585.12K1.89M
Interest Expense % of Total Revenue--118.28%505.39%-1143.80%

Balance Sheet

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets619.12K24.22M23.41M22.49M20.76M21.48M
Total Liabilities396.04K403.23K2.55M3.84M5.65M5.67M
Total Equity223.07K23.82M20.86M18.66M15.11M15.80M
Cash319.52K181.66K162.49K399.22K24.52K344.65K
Total Debt170.70K172.12K1.51M2.49M3.84M4.22M
Net Debt-148.82K-9.54K1.35M2.09M3.82M3.87M

Cash Flow

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow----1.77M-1.07M-5.52M
Investing Cash Flow-10.00K138.89K--75.93K-148.17K-736.84K
Financing Cash Flow681.55K2001.49M2.03M843.94K6.45M
Capital Expenditure00075.93K148.17K642.23K
Free Cash Flow-354.11K-276.95K-1.51M-1.85M-1.22M-6.16M
FCF to OCF---104.29%113.84%111.63%

Earnings

Report DateNov 15, 2024Jun 30, 2025Nov 17, 2025
EPS Estimate0.000.000.00
EPS Actual-0.14-0.38-0.34
Surprise---
Timing---

Key Statistics & Ratios

Market Cap5.85M
Enterprise Value9.91M
Trailing P/E0.00
Forward P/E0.00
Price / Sales12.40
Price / Book0.62
EPS-0.52
Book Value0.9151
Revenue (TTM)471.80K
Gross Profit (TTM)356.40K
EBITDA-5.14M
Profit Margin0.00%
Operating Margin-1985.28%
Return on Equity-42.93%
Return on Assets-17.61%
Shares Outstanding10.71M
Shares Float5.15M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
1.03%
Insiders
47.53%
Retail / Other
51.44%

Top Institutional Holders

  • Wedbush Morgan Securities Inc
    20.00K0.19%
  • Citadel Advisors Llc
    11.46K0.11%
  • UBS Group AG
    1.83K0.02%
  • Private Advisor Group, LLC
    00.00%
  • Two Sigma Investments LLC
    00.00%